BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 23979994)

  • 1. SUMO and Parkinson's disease.
    Eckermann K
    Neuromolecular Med; 2013 Dec; 15(4):737-59. PubMed ID: 23979994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUMO-regulated mitochondrial function in Parkinson's disease.
    Guerra de Souza AC; Prediger RD; Cimarosti H
    J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
    Betarbet R; Canet-Aviles RM; Sherer TB; Mastroberardino PG; McLendon C; Kim JH; Lund S; Na HM; Taylor G; Bence NF; Kopito R; Seo BB; Yagi T; Yagi A; Klinefelter G; Cookson MR; Greenamyre JT
    Neurobiol Dis; 2006 May; 22(2):404-20. PubMed ID: 16439141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of oxidative stress in Parkinson's disease.
    Dias V; Junn E; Mouradian MM
    J Parkinsons Dis; 2013; 3(4):461-91. PubMed ID: 24252804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parkinson's disease: what have we learned from the genes responsible for familial forms?].
    Corti O; Brice A
    Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SUMO and Alzheimer's disease.
    Lee L; Sakurai M; Matsuzaki S; Arancio O; Fraser P
    Neuromolecular Med; 2013 Dec; 15(4):720-36. PubMed ID: 23979993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New aspects of genetic contributions to Parkinson's disease.
    Hofer A; Gasser T
    J Mol Neurosci; 2004; 24(3):417-24. PubMed ID: 15655263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathophysiology of Parkinson's disease.
    Moore DJ; West AB; Dawson VL; Dawson TM
    Annu Rev Neurosci; 2005; 28():57-87. PubMed ID: 16022590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of parkin in Parkinson's disease].
    Miklya I; Göltl P; Hafenscher F; Pencz N
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):67-76. PubMed ID: 24978049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mitochondrial dysfunction and oxidative damages in the molecular pathology of Parkinson's disease].
    Shadrina MI; Slominskiĭ PA
    Mol Biol (Mosk); 2008; 42(5):809-19. PubMed ID: 18988530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMO rules: regulatory concepts and their implication in neurologic functions.
    Droescher M; Chaugule VK; Pichler A
    Neuromolecular Med; 2013 Dec; 15(4):639-60. PubMed ID: 23990202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin-proteasome system and Parkinson's diseases.
    Betarbet R; Sherer TB; Greenamyre JT
    Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways of neurodegeneration in Parkinson's disease.
    Dawson TM; Dawson VL
    Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
    Ahlskog JE
    Parkinsonism Relat Disord; 2009 Dec; 15(10):721-7. PubMed ID: 19815446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological proteins in Parkinson's disease: focus on the proteasome.
    Snyder H; Wolozin B
    J Mol Neurosci; 2004; 24(3):425-42. PubMed ID: 15655264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein degradation in Parkinson disease revisited: it's complex.
    Li H; Guo M
    J Clin Invest; 2009 Mar; 119(3):442-5. PubMed ID: 19306499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation.
    Oh Y; Kim YM; Mouradian MM; Chung KC
    Brain Res; 2011 Mar; 1381():78-89. PubMed ID: 21256122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains.
    Zucchelli S; Codrich M; Marcuzzi F; Pinto M; Vilotti S; Biagioli M; Ferrer I; Gustincich S
    Hum Mol Genet; 2010 Oct; 19(19):3759-70. PubMed ID: 20634198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sumoylation as a signal for polyubiquitylation and proteasomal degradation.
    Miteva M; Keusekotten K; Hofmann K; Praefcke GJ; Dohmen RJ
    Subcell Biochem; 2010; 54():195-214. PubMed ID: 21222284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.